Zura Bio (NASDAQ:ZURA – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.
Profitability
This table compares Zura Bio and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zura Bio | N/A | -74.71% | -38.33% |
| TScan Therapeutics | -423.86% | -60.65% | -33.86% |
Risk & Volatility
Zura Bio has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zura Bio | 0 | 0 | 4 | 1 | 3.20 |
| TScan Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Zura Bio currently has a consensus price target of $16.60, indicating a potential upside of 597.48%. TScan Therapeutics has a consensus price target of $12.50, indicating a potential upside of 57.43%. Given Zura Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Zura Bio is more favorable than TScan Therapeutics.
Institutional & Insider Ownership
61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 15.8% of Zura Bio shares are owned by insiders. Comparatively, 8.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Zura Bio and TScan Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zura Bio | N/A | N/A | $3.55 million | N/A | N/A |
| TScan Therapeutics | $21.05 million | 18.06 | -$89.22 million | ($1.89) | -4.20 |
Zura Bio has higher earnings, but lower revenue than TScan Therapeutics.
Summary
Zura Bio beats TScan Therapeutics on 7 of the 12 factors compared between the two stocks.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
